CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
Jan. 4, 2024—Sekisui Diagnostics formalized an exclusive distribution agreement with Aptitude Medical Systems to sell the Aptitude Metrix COVID-19 test in the United States. The EUA-approved, single-use molecular in vitro diagnostic test is for the qualitative detection of nucleic acid from SARS-CoV-2 using anterior nasal swab and saliva samples.
“The unique features of this test are what make this addition to our portfolio so exciting. It pairs a molecular test with a small, low-cost reader which provides highly accurate results in an affordable and simple-to-use format which can fit in the palm of your hand,” Lee Lipski, Sekisui Diagnostics’ senior VP of strategy and business management, said in a press statement. “This aligns with efforts to expand into the molecular testing market and the company’s long-term strategic vision.”